RIGID PEDICLE BONE SCREW DOWNCLASSIFICATION TO CLASS II UNANIMOUSLY RECOMMENDED
This article was originally published in The Gray Sheet
Executive Summary
RIGID PEDICLE BONE SCREW DOWNCLASSIFICATION TO CLASS II UNANIMOUSLY RECOMMENDED for the treatment of degenerative spondylolisthesis and spinal fracture by FDA's Orthopedic and Rehabilitation Devices Advisory Panel at a July 22 meeting in Gaithersburg, Maryland. The recommendation, conditioned on the development of special controls for the devices, was based on data from a retrospective study presented at the meeting. Panel member Michael Mayor, MD, Dartmouth-Hitchcock Medical Center, Hanover, New Hampshire, stated that the study provided "more than enough data to give a downclassification recommendation to FDA."
You may also be interested in...
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.